Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Functional assembly of chimeric T-cell receptor chains.

G Gorochov1, J Lustgarten, T Waks

  • 1Department of Chemical Immunology, Weizmann Institute of Science, Rehovot, Israel.

International Journal of Cancer. Supplement = Journal International Du Cancer. Supplement
|January 1, 1992
PubMed
Summary

Researchers engineered chimeric T-cell receptors (cTCR) for targeted cancer therapy. The study found that complementary chimeric chains preferentially associate, enhancing T-cell activity against tumor cells expressing the TNP hapten.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Infant gut microbiota composition and metabolism can be influenced by extensively hydrolysed casein in vitro.

Beneficial microbes·2026
Same author

[Aggressiveness and violence in daily ophthalmology practice: Descriptive analysis of a survey sent to residents and assistants in Grand Est and Bourgogne-Franche-Comté].

Journal francais d'ophtalmologie·2023
Same author

The relationship of sinus opacification, olfaction and dupilumab efficacy in patients with CRSwNP.

Rhinology·2023
Same author

Author Correction: Long-term safety and efficacy of lentiviral hematopoietic stem/progenitor cell gene therapy for Wiskott-Aldrich syndrome.

Nature medicine·2022
Same author

Telomere length and mitochondrial DNA copy number in bipolar disorder: identification of a subgroup of young individuals with accelerated cellular aging.

Translational psychiatry·2022
Same author

Long-term safety and efficacy of lentiviral hematopoietic stem/progenitor cell gene therapy for Wiskott-Aldrich syndrome.

Nature medicine·2022

Area of Science:

  • Immunology
  • Molecular Biology
  • Biotechnology

Background:

  • Cytotoxic T-lymphocyte (CTL) responses are crucial for adaptive immunity.
  • Chimeric T-cell receptors (cTCRs) offer a strategy to redirect T-cell specificity.
  • Engineering cTCRs with antibody-like specificity for haptens like TNP is a promising approach for targeted therapies.

Purpose of the Study:

  • To investigate the functional expression of chimeric T-cell receptors (cTCRs) in T-cell hybridomas.
  • To determine the role of individual chimeric TCR chains (VHC alpha and VHC beta) in receptor assembly and function.
  • To assess the ability of engineered T-cells to recognize and respond to TNP-haptenated targets.

Main Methods:

  • Generation of cytotoxic T-cell hybridomas expressing cTCRs with TNP specificity.

Related Experiment Videos

  • Transfection of chimeric VHC alpha and/or VHC beta genes into T-cell hybridomas.
  • Assessing surface expression of the TCR/CD3 complex via flow cytometry.
  • Measuring interleukin-2 (IL-2) secretion and specific cell lysis upon stimulation with TNP-modified targets.

    • Main Results:

    • Transfectants expressing cTCR genes mediated specific lysis of TNP-haptenated tumor cells and secreted IL-2.
    • Transfection of VHC alpha into an alpha-chain-defective mutant restored TCR/CD3 complex expression and partial function.
    • Double-gene transfectants with complementary chimeric chains showed high surface cTCR expression and potent anti-TNP reactivity, indicating preferential chain association.

    Conclusions:

    • Chimeric VHC alpha chains can pair with endogenous V beta C beta chains.
    • Preferential association between complementary chimeric chains (VHC alpha and VLC beta) leads to optimal functional expression of the chimeric TCR.
    • Engineered T-cells with specific cTCRs demonstrate potential for targeted immunotherapy against haptenated targets.